A First-in-Human (FIH), Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPC5001 Administered to Healthy Subjects and Subjects With Familial Hypercholesterolemia (FH)

Trial Profile

A First-in-Human (FIH), Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPC5001 Administered to Healthy Subjects and Subjects With Familial Hypercholesterolemia (FH)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2014

At a glance

  • Drugs SPC 5001 (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions
  • Sponsors Santaris Pharma
  • Most Recent Events

    • 04 Oct 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 18 May 2011 Actual initiation date changed from Apr 2011 to May 2011 as reported by ClinicalTrials.gov.
    • 09 May 2011 Planned end date (Nov 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top